Trials / Completed
CompletedNCT03518073
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 360 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 60 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zagotenemab | Administered IV |
| DRUG | Placebo | Administered IV |
Timeline
- Start date
- 2018-04-30
- Primary completion
- 2021-08-23
- Completion
- 2021-10-25
- First posted
- 2018-05-08
- Last updated
- 2022-08-30
- Results posted
- 2022-08-30
Locations
60 sites across 3 countries: United States, Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03518073. Inclusion in this directory is not an endorsement.